Moreover, Trop-2 is considered as a therapeutic target and a drug antibody conjugate targeting Trop-2— sacituzumab govitecan—has recently been approved to treat metastatic triple-negative breast cancer [28]. Here, TACSTD2 is linked to triple-negative breast carcinoma.